Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01106586
First received: April 14, 2010
Last updated: October 9, 2015
Last verified: October 2015
Results First Received: September 20, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV
HIV Infections
Interventions: Drug: Stribild
Drug: ATV
Drug: Ritonavir
Drug: FTC/TDF
Drug: Stribild Placebo
Drug: ATV Placebo
Drug: RTV Placebo
Drug: FTC/TDF Placebo

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug

Reporting Groups
  Description
Stribild Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) plus placebo to match ATV/r + FTC/TDF once daily
ATV/r + FTC/TDF ATV/r 300/100 mg tablet plus FTC 200 mg/TDF 300 mg tablet plus placebo to match Stribild once daily
Total Total of all reporting groups

Baseline Measures
   Stribild   ATV/r + FTC/TDF   Total 
Overall Participants Analyzed 
[Units: Participants]
 353   355   708 
Age 
[Units: Years]
Mean (Standard Deviation)
 38  (10.5)   39  (9.8)   38  (10.2) 
Gender 
[Units: Participants]
     
Female   29   39   68 
Male   324   316   640 
Race/Ethnicity, Customized 
[Units: Participants]
     
American Indian or Alaska Native   2   3   5 
Asian   17   17   34 
Black or African Heritage   72   47   119 
Native Hawaiian or Pacific Islander   1   2   3 
White   250   277   527 
Other   11   9   20 
Region of Enrollment 
[Units: Participants]
     
Portugal   1   2   3 
United States   197   185   382 
Thailand   7   4   11 
Austria   12   8   20 
United Kingdom   11   15   26 
Switzerland   0   2   2 
Italy   9   5   14 
France   23   23   46 
Mexico   3   2   5 
Canada   19   22   41 
Belgium   9   12   21 
Australia   30   32   62 
Denmark   1   2   3 
Netherlands   2   4   6 
Germany   29   36   65 
Sweden   0   1   1 
HIV Disease Status 
[Units: Participants]
     
Asymptomatic   285   293   578 
Symptomatic HIV Infections   36   38   74 
AIDS   32   24   56 
Hepatitis B Virus (HBV) Infection Status 
[Units: Participants]
     
Negative   347   346   693 
Positive   5   7   12 
Indeterminate   0   1   1 
Not done   1   1   2 
Hepatitis C Virus (HCV) Infection Status 
[Units: Participants]
     
Negative   335   344   679 
Positive   18   10   28 
Indeterminate   0   0   0 
Not done   0   1   1 
HIV-1 RNA Category (copies/mL) 
[Units: Participants]
     
≤ 100,000 copies/mL   203   214   417 
> 100,000 copies/mL   150   141   291 
CD4 Cell Count (/µL) 
[Units: Participants]
     
≤ 50 μL   12   5   17 
51 to ≤ 200 μL   42   34   76 
201 to ≤ 350 μL   122   124   246 
351 to ≤ 500 μL   122   122   244 
> 500 μL   55   70   125 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48   [ Time Frame: Week 48 ]

2.  Secondary:   The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 96   [ Time Frame: Week 96 ]

3.  Secondary:   The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 144   [ Time Frame: Week 144 ]

4.  Secondary:   The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 192   [ Time Frame: Week 192 ]

5.  Secondary:   The Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA-defined Time to Loss of Virologic Response (TLOVR) Algorithm   [ Time Frame: Week 48 ]

6.  Secondary:   The Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Weeks 48, 96, 144, and 192   [ Time Frame: Baseline; Weeks 48, 96, 144, and 192 ]

7.  Secondary:   The Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48   [ Time Frame: Week 48 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
There were no limitations affecting the analysis or results.


  More Information